141 related articles for article (PubMed ID: 10029060)
21. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice.
Rebel H; Kram N; Westerman A; Banus S; van Kranen HJ; de Gruijl FR
Carcinogenesis; 2005 Dec; 26(12):2123-30. PubMed ID: 16051635
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients.
Fréchet M; Warrick E; Vioux C; Chevallier O; Spatz A; Benhamou S; Sarasin A; Bernerd F; Magnaldo T
Oncogene; 2008 Sep; 27(39):5223-32. PubMed ID: 18469853
[TBL] [Abstract][Full Text] [Related]
23. Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas.
Hoogervorst EM; Bruins W; Zwart E; van Oostrom CT; van den Aardweg GJ; Beems RB; van den Berg J; Jacks T; van Steeg H; de Vries A
Cancer Res; 2005 May; 65(9):3610-6. PubMed ID: 15867355
[TBL] [Abstract][Full Text] [Related]
24. [Carcinogenesis through abnormalities of DNA repair genes].
Yokozaki H; Tahara E
Nihon Rinsho; 2000 Jun; 58(6):1237-42. PubMed ID: 10879047
[TBL] [Abstract][Full Text] [Related]
25. Reconstruction of DNA repair-deficient xeroderma pigmentosum skin in vitro: a model to study hypersensitivity to UV light.
Bernerd F; Asselineau D; Frechet M; Sarasin A; Magnaldo T
Photochem Photobiol; 2005; 81(1):19-24. PubMed ID: 15369409
[TBL] [Abstract][Full Text] [Related]
26. The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors.
Daya-Grosjean L; Sarasin A
Mutat Res; 2005 Apr; 571(1-2):43-56. PubMed ID: 15748637
[TBL] [Abstract][Full Text] [Related]
27. Effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficient XPA mice.
van Oostrom CT; Boeve M; van Den Berg J; de Vries A; Dollé ME; Beems RB; van Kreijl CF; Vijg J; van Steeg H
Environ Mol Mutagen; 1999; 34(2-3):124-30. PubMed ID: 10529736
[TBL] [Abstract][Full Text] [Related]
28. Telomere length and telomerase activity impact the UV sensitivity syndrome xeroderma pigmentosum C.
Stout GJ; Blasco MA
Cancer Res; 2013 Mar; 73(6):1844-54. PubMed ID: 23288511
[TBL] [Abstract][Full Text] [Related]
29. Mutations in the XPC gene in families with xeroderma pigmentosum and consequences at the cell, protein, and transcript levels.
Chavanne F; Broughton BC; Pietra D; Nardo T; Browitt A; Lehmann AR; Stefanini M
Cancer Res; 2000 Apr; 60(7):1974-82. PubMed ID: 10766188
[TBL] [Abstract][Full Text] [Related]
30. A novel XPC pathogenic variant detected in archival material from a patient diagnosed with Xeroderma Pigmentosum: a case report and review of the genetic variants reported in XPC.
Rivera-Begeman A; McDaniel LD; Schultz RA; Friedberg EC
DNA Repair (Amst); 2007 Jan; 6(1):100-14. PubMed ID: 17079196
[TBL] [Abstract][Full Text] [Related]
31. Xeroderma pigmentosum genes: functions inside and outside DNA repair.
Sugasawa K
Carcinogenesis; 2008 Mar; 29(3):455-65. PubMed ID: 18174245
[TBL] [Abstract][Full Text] [Related]
32. In vivo destabilization and functional defects of the xeroderma pigmentosum C protein caused by a pathogenic missense mutation.
Yasuda G; Nishi R; Watanabe E; Mori T; Iwai S; Orioli D; Stefanini M; Hanaoka F; Sugasawa K
Mol Cell Biol; 2007 Oct; 27(19):6606-14. PubMed ID: 17682058
[TBL] [Abstract][Full Text] [Related]
33. Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases.
Redondo P; Prieto J; Muñoz IG; Alibés A; Stricher F; Serrano L; Cabaniols JP; Daboussi F; Arnould S; Perez C; Duchateau P; Pâques F; Blanco FJ; Montoya G
Nature; 2008 Nov; 456(7218):107-11. PubMed ID: 18987743
[TBL] [Abstract][Full Text] [Related]
34. The relationship between benzo[a]pyrene-induced mutagenesis and carcinogenesis in repair-deficient Cockayne syndrome group B mice.
Wijnhoven SW; Kool HJ; van Oostrom CT; Beems RB; Mullenders LH; van Zeeland AA; van der Horst GT; Vrieling H; van Steeg H
Cancer Res; 2000 Oct; 60(20):5681-7. PubMed ID: 11059760
[TBL] [Abstract][Full Text] [Related]
35. Tissue specific mutagenic and carcinogenic responses in NER defective mouse models.
Wijnhoven SW; Hoogervorst EM; de Waard H; van der Horst GT; van Steeg H
Mutat Res; 2007 Jan; 614(1-2):77-94. PubMed ID: 16769089
[TBL] [Abstract][Full Text] [Related]
36. How nucleotide excision repair protects against cancer.
Friedberg EC
Nat Rev Cancer; 2001 Oct; 1(1):22-33. PubMed ID: 11900249
[TBL] [Abstract][Full Text] [Related]
37. Cell-type-specific consequences of nucleotide excision repair deficiencies: Embryonic stem cells versus fibroblasts.
de Waard H; Sonneveld E; de Wit J; Esveldt-van Lange R; Hoeijmakers JH; Vrieling H; van der Horst GT
DNA Repair (Amst); 2008 Oct; 7(10):1659-69. PubMed ID: 18634906
[TBL] [Abstract][Full Text] [Related]
38. Nucleotide excision repair- and p53-deficient mouse models in cancer research.
Hoogervorst EM; van Steeg H; de Vries A
Mutat Res; 2005 Jul; 574(1-2):3-21. PubMed ID: 15914203
[TBL] [Abstract][Full Text] [Related]
39. Dimethylbenzanthracene carcinogenesis in Gadd45a-null mice is associated with decreased DNA repair and increased mutation frequency.
Hollander MC; Kovalsky O; Salvador JM; Kim KE; Patterson AD; Haines DC; Fornace AJ
Cancer Res; 2001 Mar; 61(6):2487-91. PubMed ID: 11289119
[TBL] [Abstract][Full Text] [Related]
40. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
